Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Raymond R. Schleef is active.

Publication


Featured researches published by Raymond R. Schleef.


Journal of Clinical Investigation | 1986

Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1.

Michael P. Bevilacqua; Raymond R. Schleef; Michael A. Gimbrone; David J. Loskutoff

We examined the effects of human interleukin 1 (IL-1) on the production of fibrinolytic components by cultured human vascular endothelium. Conditioned media collected from IL-1-treated (5 U/ml, 24 h) monolayers exhibited decreased tissue-type plasminogen activator (tPA) activity and increased plasminogen activator inhibitor (PAI) activity, as assessed by fibrin and reverse fibrin-autography. Quantitative immunological assays revealed a 35% decrease in tPA antigen and a 360% increase in active PAI antigen, after incubation for 24 h with 0.6 U/ml IL-1. Maximal effects (approximately 50% decrease in tPA antigen; 400-800% increase in active PAI antigen) were observed with 2.5-5 U/ml IL-1. Changes in tPA and PAI reached a maximum at approximately 24 h and persisted for greater than 48 h. IL-1 induction of endothelial procoagulant activity was more rapid and transient, peaking by 6 h and subsiding by 24 h. Natural monocyte-derived IL-1 and two species of recombinant IL-1 had comparable effects. Heat and polymyxin-B treatments differentiated IL-1 actions from those of endotoxin, which promoted similar endothelial alterations. IL-1 effects on endothelial procoagulant and fibrinolytic activities may contribute to the generation and maintenance of fibrin in pathophysiological settings in vivo.


Mechanisms of Development | 1990

Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin

D. Seiffert; Jun Mimuro; Raymond R. Schleef; David J. Loskutoff

Regulation of plasminogen activation is a key process in controlling proteolytic events in the extracellular matrix (ECM) and this regulation is achieved through the action of specific plasminogen activator (PA) inhibitors (PAIs). Type I PAI (PAI-1) is the physiological inhibitor both of urinary-type PA (u-PA) and tissue-type PA (t-PA) (Loskutoff et al., 1989) and is a major component of the ECM of cultured cells. This inhibitor may protect ECM constituents against cellular proteases and thus influence the cell migration and tissue destruction that occurs during development, inflammation and tumor metastasis. In this review, we discuss the properties of PAI-1 and the evidence that the binding of PAI-1 to ECM is mediated by serum-derived vitronectin (Vn).


Pathophysiology of Haemostasis and Thrombosis | 1988

Fibrinolytic System of Vascular Endothelial Cells

Raymond R. Schleef; David J. Loskutoff

The regulation of the fibrinolytic system is of critical importance during hemostasis, wound repair, neoplasia, inflammation, and a variety of other biologic processes. This control is achieved in a l


Journal of Biological Chemistry | 1988

Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.

Raymond R. Schleef; Michael P. Bevilacqua; M Sawdey; Michael A. Gimbrone; David J. Loskutoff


Journal of Cell Biology | 1990

The Majority of Type 1 Plasminogen Activator Inhibitor Associated with Cultured Human Endothelial Cells Is Located under the Cells and Is Accessible to Solution-phase Tissue-type Plasminogen Activator

Raymond R. Schleef; Thomas J. Podor; Eileen Dunne; Jun Mimuro; David J. Loskutoff


Journal of Cellular Physiology | 1988

Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells

Raymond R. Schleef; Nancy Wagner; David J. Loskutoff


Thrombosis and Haemostasis | 1986

The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells.

David J. Loskutoff; Karen Roegner; Larry A. Erickson; Raymond R. Schleef; Anna Huttenlocher; Patrick L. Coleman; Thomas D. Gelehrter


Journal of Cell Biology | 1991

Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells.

Raymond R. Schleef; David J. Loskutoff; Thomas J. Podor


Methods in Enzymology | 1988

[26] Plasminogen activators and their inhibitors

David J. Loskutoff; Raymond R. Schleef


Archive | 1984

Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators

David J. Loskutoff; Raymond R. Schleef

Collaboration


Dive into the Raymond R. Schleef's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael A. Gimbrone

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

David M. Stern

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge